TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00004058
Drug: tetradecanoylphorbol acetate
Normalized name: Tetradecanoylphorbol acetate
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02244827
Drug: WCK 2349
Normalized name: Wck 771 free base
DrugBank: Levonadifloxacin (DB16219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: levonadifloxacin (active drug) and the sulfate metabolite
Study: NCT06597084
Drug: ESL 800 mg
Normalized name: ESL
DrugBank: Eslicarbazepine acetate (DB09119)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 800 mg ESL tablets for oral administration. In case a patient is unable to swallow the whole tablet, the tablet can be crushed or divided into equal doses at the score line.
Study: NCT00577382
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00755976
Drug: epirubicin hydrochloride
Normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04583410
Drug: Nicotine patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NICOPATCHLIB, 7mg/24h Day 1 to day 3 : 3,5 mg/day Day 4 to day 9 : 7 mg/day Day 10 to Day 15 : 10,5 mg/day Day 16 to day 98 : 14 mg/day~Decrease treatment Day 99 to day 105 : 10,5 mg/day Day 106 to day 112 : 7 mg/day Day 113 to Day 119 : 3,5 mg/day
Study: NCT01363999
Drug: atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose of atorvastatin on day 1
Study: NCT01363999
Drug: dalcetrapib
Normalized name: Dalcetrapib
DrugBank: Dalcetrapib (DB12181)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of dalcetrapib on day 1
Study: NCT04614142
Drug: Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]
Normalized name: glecaprevir / pibrentasvir Oral Tablet [Mavyret]
DrugBank: Pibrentasvir (DB13878)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The subject will begin an 8 week course of therapy with glecaprevir (100mg) / pibrentasvir (40mg) starting on day 3 (+/- 2 days) post-kidney transplantation from a hepatitis C positive donor.
Study: NCT03063515
Drug: Pyridostigmine
Normalized name: Pyridostigmine
DrugBank: Pyridostigmine (DB00545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single oral dose of 60 mg pyridostigmine tablet
Study: NCT01710709
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400mg or 300mg, intramuscular injections every 4 weeks.
Study: NCT04214145
Drug: Phenylephrine
Normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous infusion of Phenylenphrine 250 μg/mL (=Phenylephrine 10mg \* 5@ + D5W 200 mL) if mean BP \< 60mmHg.~1. Initial rate: 0.42 μg/kg/min (=0.1 mL/kg/hr)~2. Increment by 0.21 μg/kg/min (=0.05 mL/kg/hr) if mean BP \< 60mmHg after 5 minutes~3. Maximum rate: 3.33 μg/kg/min (=0.8 mL/kg/hr)
Study: NCT04214145
Drug: Vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous infusion of Vasopressin 0.1 u/mL (=Vasopressin 20u \* 1@ + D5W 200 mL) if mean BP \< 60mmHg.~1. Initial rate: 0.01 u/kg/hr (=0.1 mL/kg/hr)~2. Increment by 0.005 u/kg/hr (=0.05 mL/kg/hr) if mean BP \< 60mmHg after 5 minutes~3. Maximum rate: 0.08 u/kg/hr (=0.8 mL/kg/hr)
Study: NCT00218439
Drug: Paroxetine
Normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg for 1 week followed by 20 mg for 3 weeks
Study: NCT01379339
Drug: Cabazitaxel 10mg/m2
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Cabazitaxel on D1 Dose: 10mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)
Study: NCT01379339
Drug: Cabazitaxel 12.5mg/m2
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Cabazitaxel on D1 Dose: 12.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)
Study: NCT01379339
Drug: Cabazitaxel 15mg/m2
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Cabazitaxel on D1 Dose: 15mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)
Study: NCT01379339
Drug: Cabazitaxel 17.5mg/m2
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Cabazitaxel on D1 Dose: 17.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)
Study: NCT01379339
Drug: Cabazitaxel 20mg/m2
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Cabazitaxel on D1 Dose: 20mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)~* Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)~* 5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)
Study: NCT02062749
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Starting dose of Oxaliplatin is 175 mg/m2 delivered by hyperthermic intraperitoneal chemotherapy over 90 minutes.
Study: NCT02477215
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 40 mg oral on Days 1, 8, 15 of each 28 day cycle.
Study: NCT02477215
Drug: Bendamustine (multiple dose levels)
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 70 mg/m\^2, 80 mg/m\^2, or 90 mg/m\^2 on days 1 and 2
Study: NCT02477215
Drug: Bendamustine (MTD)
DrugBank: Bendamustine (DB06769)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 80 mg/m\^2 on days 1 and 2
Study: NCT04052425
Drug: Ruxolitinib cream
Normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.
Study: NCT03705858
Drug: Ac-Lintuzumab
Normalized name: 225Ac-lintuzumab
DrugBank: Lintuzumab (DB14877)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225Ac-lintuzumab will administered at 4 dose levels: 0.25, 0.5, 0.75 or 1 µCi/kg intravenously (IV) over 30 ± 10 minutes. The starting dose will be 0.5 µCi/kg. A dose of 0.25 µCi/kg will be studied only if 0.5 µCi/kg is determined to exceed the MTD. The lintuzumab dose will be adjusted to maintain a specific activity of 0.16 µCi/µg
Study: NCT03793517
Drug: Decitabine
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine 200mg.m-2.d-1 intervanously on days -12 and -11
Study: NCT04143815
Drug: MBA-P01 (Botulinum toxin A)
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Intramuscular injection, dose varies by groups
Study: NCT03651375
Drug: Sequential chemotherapy - 3 courses of AI
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three courses of doxorubicin and ifosfamide (AI, doxorubicin 75 mg/sqm and ifosfamide 10 g/sqm with prophylactic mesna), one before radiotherapy and two within the gap between radiotherapy and surgery.
Study: NCT01525966
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01525966
Drug: paclitaxel albumin-stabilized nanoparticle formulation
Normalized name: Albumin-stabilized nanoparticle (130 nm)
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT01731951
Drug: Imetelstat
Normalized name: Imetelstat
DrugBank: Imetelstat (DB14909)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imetelstat sodium administered as IV over 2 hours with treatment as long as participants derive clinical benefit or until end of study.
Study: NCT00006292
Drug: Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01720901
Drug: Icotinib
Normalized name: icotinib
DrugBank: Icotinib (DB11737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icotinib will be administered 250 mg one time by month, 3 times per day.
Study: NCT01404104
Drug: Temsirolimus (pre surgery)
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Temsirolimus will be given to patients 12 weeks prior to surgery (with a one week off period right before the surgery date).
Study: NCT01128699
Drug: Subconjunctival Avastin
Normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intraoperative Subconjunctival Avastin 1.25mg; single dose as an adjunct to 184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
Study: NCT02779842
Drug: Coppertone (BAY 987517)
DrugBank: Copper (DB09130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. formulation number SR15-39-Z12-002.
Study: NCT01460979
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 25mg weekly intravenous until progression
Study: NCT02626962
Drug: ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab every 3 weeks for a total of four doses (Cycles 1 and 2)
Study: NCT02626962
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab every 3 weeks for a total of four doses (Cycles 1 and 2) followed by Nivolumab every 2 weeks
Study: NCT04678089
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Objective To observe the safety and efficacy of bortezomib related biomarkers. Including genes, metabolites, etc
Study: NCT01065662
Drug: temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given on days 1, 8, 15 and 22 of each cycle
Study: NCT01065662
Drug: cediranib
Normalized name: cediranib
DrugBank: Cediranib (DB04849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taken orally daily
Study: NCT02256956
Drug: Amitriptyline
Normalized name: Amitriptyline
DrugBank: Amitriptyline (DB00321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg / day for 10 days
Study: NCT02256956
Drug: Tolterodine
Normalized name: Tolterodine
DrugBank: Tolterodine (DB01036)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo 1 mg / day for 10 days
Study: NCT01967927
Drug: 18F-MISO
Normalized name: 18F-MISO
DrugBank: Fluoromisonidazole F-18 (DB14830)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A radiolabeled imaging agent that has been used for investigating tumor hypoxia with positron emission tomography (PET).
Study: NCT03950271
Drug: SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1. Neoadjuvant chemotherapy： SHR-1210 (200mg, d1, q3w) + trastuzumab ( 8 mg/kg on day 1 of the first cycle, followed by 6 mg/kg every 3 weeks) + capecitabine (1000mg/m2 bid d2-15, q3w) + Oxaliplatin (130mg/m2, d2, q3w)；4cycle~2. postoperative adjuvant chemotherapy： Capecitabine (1000mg/m2 bid d1-14, q3w) + oxaliplatin (130mg/m2, d1, q3w)；The total number of chemotherapy cycles is 8 cycles.
Study: NCT04256642
Drug: Intrathecal morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal morphine at the time of spinal anesthesia
Study: NCT03978949
Drug: Bacillus Licheniformis
Normalized name: Bacillus licheniformis
DrugBank: Bacillus licheniformis (DB19247)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two weeks prior to the start of radiation therapy, the probiotics is administered three times daily until the end of radiation therapy.
Study: NCT00505765
Drug: AL-108
Normalized name: Al
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL-108, 5 mg/day- one spray in each nostril once per day
Study: NCT00505765
Drug: AL-108
Normalized name: Al
DrugBank: Aluminium (DB01370)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL-108, 30 mg/day- 3 sprays in each nostril, twice per day
Study: NCT05497570
Drug: Tenoxicam Injectable Product
Normalized name: tenoxicam Injectable Product
DrugBank: Tenoxicam (DB00469)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After arthrocentesis procedure, 2-ml injection of tenoxicam (Oksamen-L, Mustafa Nevzat İlaç Sanayi, Istanbul, Turkey) to the temporomandibular joint
Study: NCT00683852
Drug: Aripiprazole 5mg
Normalized name: ARIPIPRAZOLE 5MG TAB
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet dose of aripiprazole will be 2 mg/day during the first phase (30 days) of the study, and 5 mg/day in the second phase (30 days)
Study: NCT00683852
Drug: Aripiprazole 2mg
Normalized name: ARIPIPRAZOLE 2MG TAB
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For patients randomly assigned to the placebo/drug sequence, the dose of aripiprazole will be 2 mg/day during the second phase of the study (30 days)
Study: NCT01852565
Drug: Darapladib
Normalized name: Darapladib
DrugBank: Darapladib (DB06311)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric coated, free base (micronized) white round tablet, 160mg, Oral/repeat dose/10 days (Treatment Period 1), 14 days (Treatment Period 2)
Study: NCT01852565
Drug: Diltiazem
Normalized name: Diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended release, Blue capsule imprinted with cardizem CD and 240mg on one end, 240 mg, Oral/repeat dose/17 days
Study: NCT03852446
Drug: Indoximod HCL (F2) tablets
Normalized name: Indoximod
DrugBank: Indoximod (DB12827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The doses will be ascending per cohort from 600 mg to 2400 mg
Study: NCT03852446
Drug: Indoximod base formulation
Normalized name: Indoximod
DrugBank: Indoximod (DB12827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration of 1200 mg
Study: NCT03852446
Drug: Indoximod HCL (F2) tablets
Normalized name: Indoximod
DrugBank: Indoximod (DB12827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration of 1200 mg
Study: NCT02985996
Drug: Truvada
Normalized name: Truvada
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Truvada is intended for the treatment of HIV-1 infection. Truvada is a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg in one tablet.
Study: NCT02985996
Drug: Genvoya
Normalized name: Genvoya
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Genvoya is a 1-pill, once-a-day prescription medicine used to treat HIV-1. Genvoya is a combination of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamid in one tablet.
Study: NCT00561795
Drug: pazopanib (GW786034)
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 800 mg orally once a day for 6 cycles
Study: NCT00561795
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV over one hour every 3 weeks of 6 cycles
Study: NCT00561795
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV 175 mg/m\^2 given over 3 hours on day one of a 21 day cycle for six cycles
Study: NCT02427334
Drug: Dienogest
Normalized name: Dienogest
DrugBank: Dienogest (DB09123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: women will receive oral dienogest 2mg for 14 days starting from the 15th day of menstruation
Study: NCT01015170
Drug: bupropion HCl
Normalized name: bupropion HCl
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150mg BID for up to 8 weeks + counseling
Study: NCT03210909
Drug: BMS-986231
Normalized name: BMS-986231
DrugBank: Cimlanod (DB14983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS-986231
Study: NCT02433704
Drug: Cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin 1 gram will be given through an intraosseous cannula, placed into the medial aspect of the proximal tibia, after draping and before skin incision. The cefazolin will be administered as a bolus in 200 mL of normal saline.
Study: NCT01213121
Drug: Quetiapine
Normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral tablet/25-600mg per day/once a day/six weeks
Study: NCT04501380
Drug: AEMCOLO (Rifamycin SV MMX)
Normalized name: Aemcolo
DrugBank: Rifamycin (DB11753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be issued a patient kit containing AEMCOLO (Rifamycin SV MMX) 194 mg tablets for the 1st or the 2nd treatment regimen in a random order.
Study: NCT02116036
Drug: Rivaroxaban
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01207414
Drug: iloperidone
Normalized name: Iloperidone
DrugBank: Iloperidone (DB04946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloperidone tablets supplied at doses of 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg to achieve a target dose of 12-24 mg/day for 12 weeks.
Study: NCT01473888
Drug: T89(Dantonic)
Normalized name: santonin
DrugBank: Santonin (DB19377)
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule, 225mg B.I.D.
Study: NCT00653510
Drug: Actrapid (human insulin)
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On day one the patients will receive glucose and insulin in order to reach a blood sugar around 18 and 20 mmol/L and on day two the patients will receive glucose and insulin in order to have a blood sugar around 5 and 7 mmol/L. On both days amino acid, lipid and glucose metabolism will be assessed by means of whole body isotope dilution.
Study: NCT00416910
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00416910
Drug: Mitoxantrone
Normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00005966
Drug: thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04281095
Drug: Botulinum toxin type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Total of 20U/0.5mL is intramuscularly administered to five points of the glabellar region, 4U/0.1mL each
Study: NCT03857854
Drug: Pirfenidone
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: treatment group
Study: NCT03697252
Drug: Xanomeline and Trospium Chloride Capsules
Normalized name: trospium chloride / xanomeline Pill
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xanomeline 50 mg/trospium 20 mg BID on days 1-2 followed by xanomeline 100 mg/trospium 20 mg BID on days 3-7. The dose is increased to xanomeline 125 mg/trospium 30 mg BID on days 8-34 unless the subject is experiencing adverse events from the xanomeline 100 mg/trospium 20 mg dose. Subjects who were increased to xanomeline 125 mg/trospium 30 mg will have the option to return to xanomeline 100 mg/trospium 20 mg depending on clinical response and tolerability. Dosing must not change after Visit 7 of the study (at 21 ± 2 days of dosing) and may be decreased for tolerability reasons no more than once during the study.
Study: NCT03286114
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200mg IV every 21 days
Study: NCT02322632
Drug: Paricalcitol Capsules, 4 mcg
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paricalcitol Capsules, 4 mcg of Dr. Reddy's Laboratories Limited
Study: NCT03980665
Drug: Arsenic Trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: a arsenic class of mineral, clinically approved for treating acute promyelocytic leukemia
Study: NCT04532528
Drug: Dabigatran
Normalized name: Dabigatran
DrugBank: Dabigatran (DB14726)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran
Study: NCT03435250
Drug: AG-270
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG-270, orally, once or twice daily, on Days 1 through 28 of each 28-day cycle, until disease progression or unacceptable toxicity.
Study: NCT02369874
Drug: MEDI4736 + Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI4736 + Tremelimumab combination therapy
Study: NCT03435250
Drug: AG-270
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG-270, orally, once or twice daily, for 1 week prior to the first dose of docetaxel. Thereafter, AG-270 continues to be given daily, on Days 1 through 21 of each 21-day cycle, until disease progression or unacceptable toxicity.
Study: NCT03435250
Drug: AG-270
Normalized name: AGS-499
DrugBank: AGS-499 (DB18058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG-270, orally, once or twice daily for 1 week prior to the first doses of nab-paclitaxel and gemcitabine. Thereafter, AG-270 continues to be given daily on Days 1 through 28 of each 28-day cycle, until disease progression or unacceptable toxicity.